Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells-Reference-Cited by-同舟云学术

Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells

Published:2017-02-10 Issue:4 Volume:60 Page:1309-1324
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Banerjee Souvik¹²,Norman Derek D.¹²,Lee Sue Chin¹²,Parrill Abby L.¹²,Pham Truc Chi T.¹²,Baker Daniel L.¹²,Tigyi Gabor J.¹²,Miller Duane D.¹²^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, College of Pharmacy, ‡Department of Physiology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States

2. Department of Chemistry, ∥Computational Research on Materials Institute, The University of Memphis, Memphis, Tennessee 38152, United States

Funder

Center for Strategic Scientific Initiatives, National Cancer Institute

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b01270

Reference39 articles.

1. Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature

2. Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif

3. Chemical Evolution of Autotaxin Inhibitors

4. Lysophospholipid receptors in drug discovery

5. Aiming drug discovery at lysophosphatidic acid targets

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Autotaxin Inhibitor ATX-1d Significantly Enhances Potency of Paclitaxel—An In Silico and In Vitro Study;Molecules;2024-09-10

2. Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review;Pharmaceutics;2024-08-01

3. BBT-877, a Novel Autotaxin Inhibitor, Abrogates Drug Resistance in Epithelial Ovarian Cancer Stem Cells;Anticancer Research;2024-02-29

4. Multipathway regulation induced by 4‐(phenylsulfonyl)morpholine derivatives against triple‐negative breast cancer;Archiv der Pharmazie;2024-02-05

5. A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma;Lipids in Health and Disease;2024-01-22